CD Bioparticles Launches Custom Latex Immunoturbidimetric Assay (LIA) Development Services to Accelerate IVD Innovation

Sep 22, 2026

CD Bioparticles launches end-to-end Custom Latex Immunoturbidimetric Assay development services for research applications.

New York, NY, United States, September 22, 2026 /MarketersMEDIA/ -- With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the expansion of its diagnostic capabilities with the launch of its end-to-end Custom Latex Immunoturbidimetric Assay development services. These services offer full-spectrum assay customization ranging from particle conjugation to fully optimized kit assembly, and can help researchers and diagnostic developers to streamline IVD reagent manufacturing and clinical biomarker quantification.

The immunoturbidimetry method is an analytical technique combining liquid-phase precipitation reactions with optical instruments and automated analysis. However, due to issues relating to the size and quantity of antigen-antibody complexes, the immunoturbidimetry has low sensitivity and a narrow detection range. This has led to the development of the latex immunoturbidimetric assay (LIA). This technique uses latex microparticles that are coated with specific antibodies or antigens.

When these particles encounter the target analyte in a sample, they form specific aggregates through antigen-antibody interactions. The aggregation of these particles increases the scattering intensity or absorbance of the latex suspension. This increase is quantitatively correlated with the concentration of the target analyte in the sample. Turbidity measurements are performed using a biochemical analyser, and the entire analytical process takes only a few minutes. Compared to traditional immunoturbidimetric methods, this method offers significantly higher sensitivity, with detection limits as low as ng/mL or pg/mL.

CD Bioparticles has extensive experience in assay solutions and now offers custom services to help researchers and diagnostic product developers develop latex immunoturbidimetric assays. The company's service portfolio ranges from custom conjugation to the optimization of complete immunoturbidimetric assays. The company provides custom-made, carboxyl-functionalized polystyrene microspheres that are conjugated with antigens or antibodies and come in various sizes. CD Bioparticles also offers complete kits for the quantitative detection of a wide range of biomarkers. These products feature high sensitivity, short assay times and compatibility with automated biochemical analyzers.

CD Bioparticles offers customers carboxyl-modified polystyrene microparticles in a range of sizes (from 0.07 to 0.4 μm) that are suitable for developing latex immunoturbidimetric assay reagents. CD Bioparticles' standard products feature a moderate surface carboxyl density; products with higher or lower densities are also available upon request. Additionally, CD Bioparticles can customize the conjugation of antibodies and antigens to meet specific application requirements. Through optimization, the team can ensure high conjugation efficiency while maintaining the activity of both antibodies and antigens.

CD Bioparticles also offers reagent formulation development and optimization services to help customers improve reagent stability, optimize reaction conditions and enhance detection sensitivity. The company offers performance validation services to verify key performance indicators, including linearity, sensitivity, specificity and precision, ensuring stability across different batches and under various operating conditions.

For more information about CD Bioparticles' Custom Latex Immunoturbidimetric Assay development services or to submit a project inquiry, please visit https://www.cd-bioparticles.com/services/latex-immunoturbidimetric-assay-development.html.

About CD Bioparticles

CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.

Contact Info:
Name: Richard J. Gray
Email: Send Email
Organization: CD Bioparticles
Website: https://www.cd-bioparticles.com/

Release ID: 89204007

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.

MORE NEWS

The uncomfortable truth about aquariums

Sep 22, 2026

The uncomfortable truth about aquariums

Young visitors watch the beluga whales at L'Oceanogràfic in Valencia, Spain. | Miguel Candela/SOPA Images/LightRocket via Getty Images This story appeared in Today, Explained, a daily newsletter that helps you understand the most compelling news and stories of the day. Subscribe here. Four beluga whales have died in a month at one of America’s top-rated aquariums — a tragic development and, arguably, a reason to revisit the ethics of zoos. (More on that in just a minute.) The latest cetacean casualty, a 26-year-old female named Osiris, died at Chicago’s Shedd Aquarium yesterday. She follows 34-year-old Beethoven, a longtime resident of the aquarium, as well as 20-year-old Rain and 23-year-old Peekachu, who died in late August and early September.    Osiris, Rain and Peekachu were all part of the Marineland diaspora: a group of four dolphins and 30 beluga whales that rescuers have worked to relocate since the 2024 closure of a scandal-plagued theme park in Niagara Falls, Canada. This summer, the animals were successfully transferred to aquariums and marine parks in the US and Spain. That was a frankly incredible undertaking involving padded shipping containers, a police-escorted convoy and a chartered plane.  But in some regards, the international flight wasn’t even the hardest part of the whales’ journeys. Some of the animals have struggled to thrive in their new environments — even when those environments are state-of-the-art, like Shedd.  In a blog post announcing Osiris’s death, the aquarium noted that its rescued whales had been under 24-hour supervision and receiving intensive, specialized care. The aquarium is still investigating the cause of death for all four whales.  Go a little deeper View Link Believe me when I tell you that it gives me no pleasure to write the following paragraphs. I really love aquariums. In fact, as a kid, I grew up visiting the now-shuttered and much-maligned Marineland.  But incidents like these back-to-back deaths should prompt us all to ask ourselves who aquariums and zoos are actually for. And the answer, I regret to tell you, is frequently not “the animals” — though zoos and aquariums have, since the mid-20th century, marketed themselves as both tourist attractions and important players in wildlife education and conservation.   As my colleague Kenny Torrella writes, these institutions and their defenders argue they protect animals in three ways: first, by raising money for wildlife conservation projects; second, by helping to reintroduce vulnerable species back into the wild; and third, by inspiring visitors to take an interest in the environment. The Shedd Aquarium’s motto, for instance, is “For Love of Waterkind.”  It’s worth scrutinizing those purported virtues, however — even when prestigious and reputable institutions like Shedd are making them. On one hand, there is merit to the claim that zoos and aquariums fundraise for wildlife conservation: In 2022, the latest year for which data is available, one group of accredited zoos and aquariums spent more than a quarter of a billion dollars on habitat projects.  The evidence is thinner on the other points, though. It’s incredibly rare for aquariums and zoos to reintroduce endangered species back into the wild — that’s very difficult to do. And surveys of zoo and aquarium visitors show that merely seeing a wild animal in a tourist setting doesn’t generally galvanize people on matters of welfare or stewardship. Living in captivity in that tourist setting, however, can be stressful (or worse) for the animals themselves.  But what would a humane alternative look like? Even if zoos and aquariums stopped catching animals in the wild, that would still leave many thousands who are injured, orphaned, born in captivity, or otherwise accustomed to human care.  When it comes to whales, one nonprofit advocacy organization is already working on an alternative: a 110-acre coastal sanctuary for “retired” whales. That project, however, is still a long way from completion. And in the meantime, it’s up to consumers to decide whether the stated benefits of zoos and aquariums outweigh the potential harms to the animals they exhibit. One link for later ➨ Beware the trap of “moral perfection.” We should all endeavor to live lives that embody our values, sure. But if you never board a plane because you care about the climate, or you never take your kid to zoos because you read the arguments above, then you might end up with a smaller, less-lived life. And that’s no good, either.  Before you go… Did you know…that there have been “revolutionary” advancements in Alzheimer’s treatments in just the past five years? Two new drugs both markedly slow the progress of dementia. Today’s trivia: Geography time! What country is bordered by Chad to the east and Mali to the west? Hint: It is the second-largest landlocked African nation. (You can find this and other brain puzzles in Vox’s daily crossword. Look for the answer in tomorrow’s edition.) Yesterday’s trivia: Yesterday we asked you for the classic Broadway star who first sang hits including “There’s No Business Like Show Business.” That would be Ethel Merman, whom one biographer dubbed “the most successful musical comedy performer of her generation.”

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

ABOUT US
Logo

We believe that information is the new age currency. Digital Press Network is your source for digital culture and innovation for the connected generation.

SUBSCRIBE
Copyright © 2015 - 2026 Digital Press Network. All Rights Reserved.